JP Morgan Chase
VTGN icon

JP Morgan Chase’s VistaGen Therapeutics VTGN Stock Holding History

JP Morgan Chase’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5 Sell
16
-66
-80% -$17 ﹤0.01% 8126
2026
Q2 		$62 Buy
82
+66
+413% +$40 ﹤0.01% 7573
2026
Q1 		$9 Hold
16
– – ﹤0.01% 7440
2025
Q4 		$11 Sell
16
-271,809
-100% -$982K ﹤0.01% 7330
2025
Q3 		$965K Sell
271,825
-477,037
-64% -$1.43M ﹤0.01% 4625
2025
Q2 		$1.5M Sell
748,862
-2,014
-0.3% -$4.58K ﹤0.01% 4121
2025
Q1 		$1.88M Sell
750,876
-21,368
-3% -$60.5K ﹤0.01% 3924
2024
Q4 		$2.28M Buy
772,244
+772,228
+4,826,425% +$2.17M ﹤0.01% 4050
2024
Q3 		$48 Hold
16
– – ﹤0.01% 7128
2024
Q2 		$56 Hold
16
– – ﹤0.01% 7008
2024
Q1 		$84 Hold
16
– – ﹤0.01% 6939
2023
Q4 		$82 Hold
16
– – ﹤0.01% 7143
2023
Q3 		$84 Sell
16
-465
-97% -$2.06K ﹤0.01% 6931
2023
Q2 		$899 Sell
481
-4,819
-91% -$16.9K ﹤0.01% 6470
2023
Q1 		$20K Buy
5,300
+1,610
+44% +$8.44K ﹤0.01% 5978
2022
Q4 		$11K Buy
3,690
+63
+2% +$237 ﹤0.01% 6014
2022
Q3 		$17K Buy
3,627
+152
+4% +$1.51K ﹤0.01% 5854
2022
Q2 		$92K Buy
3,475
+437
+14% +$15.4K ﹤0.01% 5456
2022
Q1 		$113K Buy
3,038
+535
+21% +$23.3K ﹤0.01% 5451
2021
Q4 		$147K Sell
2,503
-4,008
-62% -$261K ﹤0.01% 5510
2021
Q3 		$536K Sell
6,511
-430
-6% -$37.4K ﹤0.01% 4677
2021
Q2 		$656K Buy
+6,941
New +$514K ﹤0.01% 4532

Other funds holding VTGN

Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
AdvisorShares Investments
AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

JP Morgan Chase's VTGN Position: Q3 2026 in Review

JP Morgan Chase reduced its VistaGen Therapeutics (VTGN) stake by 80% in Q3 2026, selling an estimated $17 and leaving 16 shares worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #8126.

JP Morgan Chase first reported a position in VTGN in Q2 2021 and has held it in 22 quarters since. The position peaked at $2.28M in Q4 2024. 22 funds tracked by Wall St. Rank hold VTGN as of Q3 2026.

  • JP Morgan Chase held 16 shares of VistaGen Therapeutics worth $5 as of Q3 2026.
  • JP Morgan Chase sold 66 VistaGen Therapeutics shares in Q3 2026, an estimated $17.
  • VistaGen Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #8126 holding.
  • JP Morgan Chase first reported a position in VistaGen Therapeutics in Q2 2021 and has held it in 22 quarters since.
  • JP Morgan Chase's VistaGen Therapeutics position peaked at $2.28M in Q4 2024.
  • 22 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.